Trial Profile
An Open-label, Randomised, Non-comparative Phase 2 Study Evaluating S 95005 (TAS-102) Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Metastatic COlorectal Cancer Who Are Non-eligible for Intensive Therapy (TASCO1 Study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Apr 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary) ; Capecitabine
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms TASCO1
- Sponsors Servier
- 19 Apr 2022 Results of final overall survival, published in the British Journal of Cancer
- 17 Jan 2021 Result assessing final end-of-study analysis on the overall survival (OS) presented at the 2021 Gastrointestinal Cancers Symposium.
- 16 Jan 2021 Updated results presented in the Servier Media Release.